Sartorius Stedim Biotech (CHIX:DIMP) Long-Term Debt: €1,861 Mil (As of Mar. 2026)


CHIX:DIMP Sartorius Stedim Biotech SA CHIX:DIMP
84 GF Score
Price €179.55
GF Value €207.75
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Sartorius Stedim Biotech Long-Term Debt?

Sartorius Stedim Biotech CHIX:DIMP 84 Long-Term Debt is €1,861 Mil as of Mar. 2026. GuruFocus rates CHIX:DIMP with a GF Score™ of 84/100 and a GF Value™ of €207.75 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Sartorius Stedim Biotech's Long-Term Debt for the quarter that ended in Mar. 2026 was €1,861 Mil.

Sartorius Stedim Biotech's quarterly Long-Term Debt increased from Sep. 2025 (€1,867 Mil) to Dec. 2025 (€1,867 Mil) but then declined from Dec. 2025 (€1,867 Mil) to Mar. 2026 (€1,861 Mil).

Sartorius Stedim Biotech's annual Long-Term Debt declined from Dec. 2023 (€3,510 Mil) to Dec. 2024 (€2,684 Mil) and declined from Dec. 2024 (€2,684 Mil) to Dec. 2025 (€1,867 Mil).

Sartorius Stedim Biotech  (CHIX:DIMp) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Sartorius Stedim Biotech Long-Term Debt Related Terms

Sartorius Stedim Biotech Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Sartorius Stedim Biotech's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sartorius Stedim Biotech Long-Term Debt Chart

Sartorius Stedim Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 521.10 1,020.70 3,509.80 2,684.40 1,867.40

Sartorius Stedim Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,683.60 2,684.20 1,866.70 1,867.40 1,860.50
CHIX:DIMP
84GF Score
Sartorius Stedim Biotech SA CHIX:DIMP
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €1,861 Mil mean?
Sartorius Stedim Biotech (CHIX:DIMP) has a Long-Term Debt of €1,861 Mil as of Mar. 2026.
Is Sartorius Stedim Biotech's Long-Term Debt too high?
Sartorius Stedim Biotech's current Long-Term Debt is €1,861 Mil. Overall, Sartorius Stedim Biotech has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Long-Term Debt compare to ISRG and BDX?
Sartorius Stedim Biotech's Long-Term Debt of €1,861 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Sartorius Stedim Biotech's current Long-Term Debt is €1,861 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Modestly Undervalued. The stock's GF Value™ is €207.75, compared to a current price of €179.55 — trading 13.6% below its estimated fair value. The current Long-Term Debt is €1,861 Mil. Sartorius Stedim Biotech's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current Long-Term Debt is €1,861 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued. The current stock price of €179.55 is trading 13.6% below its estimated GF Value™ of €207.75. GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.

Key valuation signals for CHIX:DIMP:

  • Long-Term Debt: €1,861 Mil
  • GF Value™: €207.75 vs. price of €179.55 (13.6% below fair value)
  • GF Score™: 84/100 with 5 warning signs

No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sartorius Stedim Biotech Business Description

Address Otto-Brenner-Strasse 20, Goettingen, DEU, 37079
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
84GF Score

Get the complete analysis for CHIX:DIMP

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€179.55
Price
€207.75
GF Value